UdayDandamudiMD

PubMed

• Rapid Hepatomegaly From Ruxolitinib Discontinuation Syndrome.
  Ryan Jansen van Rensburg, Shayna Hale, Anna Calara, Kulveer Dabb, Uday Dandamudi, Parth Desai> ;HCA Healthcare Journal of Medicine. 2023 Jan 1
• 23 citations
  A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study.
  Uday B. Dandamudi, Musie Ghebremichael, Jeffrey A. Sosman, Joseph I. Clark, David F. McDermott, Michael B. Atkins, Janice P. Dutcher, Walter J. Urba, Meredith M. Regan...> ;Journal of Immunotherapy. 2013 Nov 1
• 30 citations
  The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer.
  Geoffrey I. Shapiro, Richard G. Frank, Uday B. Dandamudi, Thomas Hengelage, Lily Zhao, Lucien Gazi, Maria Grazia Porro, Margaret M. Woo, Lionel D. Lewis> ;Cancer Chemotherapy and Pharmacology. 2012 Feb 1
• 4 citations
  Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer
  Uday B. Dandamudi, Laurel M. Adams, Brendan M. Johnson, John W. Bauman, Shannon R. Morris, Sharon C. Murray, R. Timothy Webb, Elaina M. Gartner, Raymond J. Hohl, Lione...> ;Cancer Chemotherapy and Pharmacology. 2011 Apr 1
• 10 citations
  Warfarin genotyping using three different platforms.
  Joel A. Lefferts, Mary C. Schwab, Uday B. Dandamudi, Hong-Kee Lee, Lionel D. Lewis, Gregory J. Tsongalis> ;American Journal of Translational Research. 2010 Jul 25
• Influence of food on the pharmacokinetics (PK) of panobinostat (LBH589), an orally active histone deacetylase inhibitor, in patients with advanced cancer.
  Lewis L, Frank R, Dandamudi UB, Gallagher J, Zhao L, Woo M, Hirawat S, Shapiro GI> ;J. Clin. Oncol.. 2009-05-20
• An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Coopersto...
  Goh, B. C., Reddy, N. J., Dandamudi, U. B., Laubscher, K. H., Peckham, T., Hodge, J. P., Suttle, A. B., Arumugham, T., Xu, Y., Xu, C. F., Lager, J., Dar, M. M., Lewis,...> ;Clin Pharmacol Ther. 2010 Nov
• Join now to see all

Abstracts/Posters

• A Phase-I dose escaIatìon study of cycIIcaI Weekly Temozolomide (TMZ) combined with weekly PegyIated Interferon AIfa-Zb (PEG-IFN) in patients (pts) with refractory and...
  Dandamudi UB. BeeIan AP, Reddy NJ, Crosby NC, Ernstoff IVIS & Lewis LD, CIin Pharm & Ther
• Comparative study of CYPZCQ and VKORC1 (-1639G>A) genotyping with the Nanopshere Verigene System and the Third VVave Gtechnologies invaderAssay.
  Dandamudi UB, Lefferts JA, Schwab MC, Bean JR, Lee HK, Tsongalis GJ, Lewis LD, The lXth World Conference on Clinical
• Effect of oral (PO) casopitant, a novel NK~1 receptor antagonist, on the pharmacokinetics (PK) and safety profile of intravenous (IV) docetaxel.
  Adams L, Johnson B, Bauman J, Lebowitz P, Zhang, K. Webb, T. Gartner, E. Hohl R, Dandamudi UB. & Lewis, L, EJC Supplements Iss
• Effect of casopitant, a novel NK-t receptor antagonist, on the pharmacokinetics (pk) and pharmacodynamics (pd) of docetaxel in cancer patients (pts).
  Dandamudi UB, Balan SB, Gartner EM, Webb RT, Hohi RJ, Adams LM, Bauman J, Johnson B, Murray S, Morris S, Lewis LD, Clin Pharm & Ther
• KRAS mutation detection: A Clinical Experience.
  Dandamudi UB, Schwab MC, Lefferts JA, Suriavvinata AA, Pìpas MJ, Tsongalis GJ, Northern New England Clinical Oncology Society
• Influence of food on the pharmacokinetics (PK) of panobinostat (LBH589), an orally active Histone Deacetylase inhibitor, in patients with advanced cancer.
  Lewis LD, Frank R, Dandamudi UB, Gallagher J, Zhao L, VVoo MM, Hirawat S & Shapiro G, ASCO 2009 Annual Meeting
• Join now to see all